Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients
- 217 Downloads
Corticosteroids are commonly used to alleviate symptoms from cerebral vasogenic edema in glioblastoma (GBM) patients. This study evaluated the impact of overall corticosteroid exposure during chemoradiotherapy (CRT) on acute severe lymphopenia (ASL) and survival outcomes of GBM patients.
GBM patients treated with CRT from 2007 to 2016 were retrospectively analyzed. Overall corticosteroid exposure was estimated as the average daily dexamethasone dose during 6 weeks of CRT. ASL was defined as grade 3 or higher lymphopenia within 3 months of starting CRT. ASL rates, overall survival (OS), and progression-free survival (PFS) were analyzed using Kaplan–Meier method. Multivariable analysis (MVA) was performed using logistic and Cox regression to identify independent predictors of ASL and survival outcomes, respectively.
Of the 319 eligible patients, the median daily dexamethasone use was 2 mg/day. The high-dose dexamethasone cohort (> 2 mg/day) had significantly higher ASL and worse OS than the low-dose dexamethasone cohort: 3-month ASL of 43.7% versus 19.8% (p < 0.003) and median OS of 12.6 months versus 17.9 months (p < 0.001), respectively. On MVA, higher dexamethasone use was independently associated with higher ASL and worse OS, but not worse PFS. A subset analysis of patients with gross-total resection found that higher dexamethasone use was significantly associated with ASL, but not OS.
Increased corticosteroid use among GBM patients during CRT appears to be an independent risk factor for developing subsequent ASL. Its apparent association with worse OS may be influenced by other confounding factors and would need to be validated through prospective investigations.
KeywordsGlioblastoma Corticosteroids Lymphopenia Chemoradiotherapy
The authors would like to acknowledge Dan Mullen and Sandra Fergus for their tremendous support in data management and acquisition of radiation dosimetric data.
Compliance with ethical standards
Conflict of interest
J.H. reports research support from Pfizer and Cantex, personal fees from Viewray, outside the submitted work. J.L.C reports research support from NeoImmuneTech Inc. and Incyte Corporation, outside the submitted work. The remaining authors declare no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was waived for this study after evaluation of methodology by Institutional Review Board.
- 7.Huang J, Dewees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S et al (2015) Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys 92(5):1000–1007. https://doi.org/10.1016/j.ijrobp.2015.04.005 CrossRefPubMedGoogle Scholar
- 16.Shields LBE, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S et al (2015) Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol 10(1):222CrossRefPubMedPubMedCentralGoogle Scholar